UniQure Shares Plummet After FDA Says AMT-130 Trial Data Insufficient for Approval
Shares of UniQure NV (NASDAQ: QURE) fell sharply after the U.S. Food and Drug Administration notified the company that data from its early- to mid-stage AMT-130 gene therapy trial for Huntington’s disease would not support a marketing application. The agency concluded the trial results, when assessed against an external control, do not meet the sta…